Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Compounds to be developed for selected inflammatory diseases

BTG : 03 October, 2006  (Company News)
BTG, the global technology commercialisation company, announced today that it is seeking partners to develop and commercialise its PDE-4 inhibitor portfolio for specific inflammatory indications outside of respiratory disease.
BTG, the global technology commercialisation company, announced today that it is seeking partners to develop and commercialise its PDE-4 inhibitor portfolio for specific inflammatory indications outside of respiratory disease.

PDE-4 inhibitors are candidates for the treatment of a wide array of serious conditions, including asthma and chronic obstructive pulmonary disease, and non-respiratory indications such as cognitive disorders, multiple sclerosis, osteoporosis, contact dermatitis and rheumatoid arthritis. To date, most development programs have focused on the treatment of respiratory disease. While positive clinical results have recently been reported for this class of compounds in chronic-obstructive pulmonary disease, other results have been mixed, most likely due to compound-specific issues around efficacy and/or toxicity.

Pre-clinical studies investigating BTGs proprietary compounds have demonstrated encouraging efficacy and safety profiles, which may signify an important advancement in the development of new therapies for a variety of inflammatory diseases, including multiple sclerosis, contact dermatitis, and osteoporosis.

In addition to the encouraging pre-clinical results, we believe that pursuit of select indications outside of the respiratory disease area may represent a more rapid path through the clinic due to the specific types of clinical trials that are required, said Thomas Logan, Ph.D., Vice President of BTGs Biopharmaceuticals Business Unit. We look forward to working with development partners to explore these non-respiratory indications for our proprietary PDE-4 inhibitors.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo